Aurora Cannabis (ACB) Q3 2026 Earnings Transcript

Core Insights - The company is a leading player in the global medical cannabis market, with a strong focus on international markets and compliance with stringent regulatory standards [1][3][23] - The company reported a 7% increase in net revenue, driven by a 12% growth in global medical cannabis revenue, with international sales growing by 17% [3][17] - The company is strategically exiting lower-margin consumer cannabis markets in Canada to focus on higher-margin medical cannabis operations [4][5][14] Financial Performance - Adjusted gross margin increased by 100 basis points to 62%, with medical cannabis margins at 69% due to growth in higher-margin international markets [2][16] - Adjusted EBITDA was reported at $18.5 million, with adjusted net income of $7.2 million and positive free cash flow of $15.5 million [2][17] - The company ended the quarter with $154 million in cash and no cannabis-related debt, maintaining a strong balance sheet [2][20] Market Strategy - The company is reallocating resources from the Canadian consumer cannabis segment to enhance its global medical cannabis business, which is expected to drive profitability [4][5][14] - The company plans to divest its lower-margin plant propagation operations to focus on higher-margin segments [5][32] - The company is expanding its product offerings in key international markets, including Germany and Australia, to capture growth opportunities [6][10][12] International Market Insights - Germany is highlighted as a significant market, with imports expected to double in 2025, driving the company's international revenue growth [7][9] - The Australian market is seen as a $1 billion opportunity, with efforts to shift sales towards premium products to improve margins [9][10] - The company is actively exploring new international markets, including Switzerland, Austria, and Turkey, to expand its footprint [50][57] Future Outlook - Annual global medical cannabis net revenue is projected to increase to between $269 million and $281 million, driven by 10% to 15% growth in the global medical cannabis segment [21][20] - Consolidated adjusted EBITDA is anticipated to grow by 5% to 10% year-over-year, reflecting the company's focus on high-margin medical cannabis operations [21][20] - The company is committed to maintaining its leadership position in the global medical cannabis market while exploring strategic opportunities for growth [23][46]